



# Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)”

Rosa De Miguel,<sup>a,e</sup> David Rial-Crestelo,<sup>b,e</sup> Lourdes Dominguez-Dominguez,<sup>b</sup> Rocío Montejano,<sup>a</sup> Andrés Esteban-Cantos,<sup>a</sup> Paula Aranguren-Rivas,<sup>b</sup> Natalia Stella-Ascariz,<sup>a</sup> Otilia Bisbal,<sup>b</sup> Laura Bermejo-Plaza,<sup>b</sup> Mónica García-Alvarez,<sup>b</sup> Belén Alejos,<sup>c</sup> Asunción Hernando,<sup>d</sup> Mireia Santacreu-Guerrero,<sup>b</sup> Julen Cadiñanos,<sup>a</sup> Mario Mayoral,<sup>a</sup> Juan Miguel Castro,<sup>a</sup> Victoria Moreno,<sup>a</sup> Luz Martín-Carbonero,<sup>a</sup> Rafael Delgado,<sup>b</sup> Rafael Rubio,<sup>b</sup> Federico Pulido,<sup>b,f,\*</sup> and José Ramón Arribas,<sup>a,f,\*\*</sup> ART-PRO, P116/00837-P116/00678 study group

<sup>a</sup>Hospital Universitario La Paz – IdiPAZ. Paseo de la Castellana 261, 28046, Madrid, Spain

<sup>b</sup>Hospital Universitario 12 de Octubre - Imas12, Av. de Córdoba, s/n, 28041, Madrid, Spain

<sup>c</sup>Instituto de Salud Carlos III, Av. de Monforte de Lemos, 5, 28029, Madrid, Spain

<sup>d</sup>Universidad Europea de Madrid- Imas12, Calle Tajo, s/n, 28670 Villaviciosa de Odón, Madrid, Spain

The authors wish to acknowledge that the study was conducted using FEDER funds. The updated acknowledgment section is presented below.

## Acknowledgments

This study was funded by Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III P116/00837 - P116/00678. Project financed with FEDER funds. RDM is supported by a Rio Hortega fellowship from Fondo de Investigaciones Sanitarias (CM17/00064). M.G.A is supported by “Instituto de Salud Carlos III” (JR15/00031). AE is supported by a PFIS fellowship from Fondo de Investigaciones Sanitarias (FI17/00194). JC is supported by a Rio Hortega fellowship from Fondo de Investigaciones Sanitarias (CM19/00059).

The authors thank the study participants; their families and caregivers; investigators and site staff who participated in the study.

eBioMedicine  
2023;89: 104486  
Published Online 18  
February 2023  
<https://doi.org/10.1016/j.ebiom.2023.104486>

DOI of original article: <https://doi.org/10.1016/j.ebiom.2020.102779>

\*Corresponding author. Unidad VIH. Centro de Actividades Ambulatorias 2ª Planta Bloque, D. Hospital 12 de Octubre. Av. Córdoba s/n. 28041-Madrid, Spain.

\*\*Corresponding author. Infectious Diseases Unit, Internal Medicine Service, Hospital La Paz, IdiPAZ, Castellana 261, 28046, Madrid, Spain.

E-mail addresses: [federico.pulido@salud.madrid.org](mailto:federico.pulido@salud.madrid.org) (F. Pulido), [joser.arribas@salud.madrid.org](mailto:joser.arribas@salud.madrid.org) (J.R. Arribas).

© 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

<sup>c</sup>Contributed equally.

<sup>f</sup>Co-senior authors.